Literature DB >> 2529761

Usefulness of total 12-lead QRS voltage compared with other criteria for determining left ventricular hypertrophy in hypertrophic cardiomyopathy: analysis of 57 patients studied at necropsy.

A L Dollar1, W C Roberts.   

Abstract

PURPOSE: The sensitivity of electrocardiographic indicators of left ventricular (LV) hypertrophy is known to be rather poor. To date, no study has undertaken a comparison of the various electrocardiographic criteria for LV hypertrophy among patients with hypertrophic cardiomyopathy (HC). In this study, we compared the sensitivity of the total 12-lead QRS amplitude with the sensitivity of certain standard electrocardiographic criteria for LV hypertrophy in necropsy patients with HC.
MATERIALS AND METHODS: A total of 57 hearts were studied. The last technically satisfactory electrocardiogram available from each necropsy patient was used. Electrocardiographic criteria employed to diagnose LV hypertrophy included the Sokolow and Lyon index, the Romhilt-Estes voltage criteria, the Romhilt-Estes point score, the ratio of RV6:RV5 greater than 1 proposed by Holt and Spodick, and a method utilizing the sum of the amplitudes of the QRS complexes of all 12 leads.
RESULTS: The total 12-lead QRS amplitude ranged from 66 to 339 mm (mean: 197 mm) (10 mm = 1 mV). Using 175 mm as the upper limit of normal, this technique yielded a sensitivity of 53%, which was the highest sensitivity of any criteria tested. The Sokolow-Lyon index had a sensitivity of 39%; the Romhilt-Estes voltage criteria, 37%; the Romhilt-Estes point score system, 49%; and the criterion of RV6 more than RV5, 39%. No correlation was found between total 12-lead QRS voltage and heart weight, LV free wall thickness, LV peak systolic and end-diastolic pressures, or LV outflow tract peak systolic pressure gradient. The 10 patients (18%) with transmural LV scars had significantly lower total 12-lead QRS voltage than did the 48 patients (78%) without such scars (155 mm versus 205 mm, p = 0.02).
CONCLUSION: Total 12-lead QRS amplitude more than 175 mm is a useful indicator of LV hypertrophy and, among patients with HC, it is more sensitive than other more commonly employed criteria.

Entities:  

Mesh:

Year:  1989        PMID: 2529761     DOI: 10.1016/s0002-9343(89)80817-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Facts and principles learned at the 32nd annual Williamsburg Conference on Heart Disease.

Authors:  William Clifford Roberts; Hassan Farooq
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-04

2.  William Clifford Roberts, MD: an interview by W. Bruce Fye, MD.

Authors:  William C Roberts; W Bruce Fye
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

3.  Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy.

Authors:  Neal K Lakdawala; Jens Jakob Thune; Barry J Maron; Allison L Cirino; Ole Havndrup; Henning Bundgaard; Michael Christiansen; Christian M Carlsen; Jean-François Dorval; Raymond Y Kwong; Steven D Colan; Lars V Køber; Carolyn Y Ho
Journal:  Am J Cardiol       Date:  2011-09-21       Impact factor: 2.778

4.  Usefulness of Total 12-Lead QRS Voltage as a Clue to Diagnosis of Patients With Cardiac Sarcoidosis Severe Enough to Warrant Orthotopic Heart Transplant.

Authors:  William C Roberts; Tiffany M Becker; Shelley A Hall
Journal:  JAMA Cardiol       Date:  2018-01-01       Impact factor: 14.676

5.  Electrocardiographic criteria of left ventricular hypertrophy in general population.

Authors:  Edoardo Casiglia; Laura Schiavon; Valérie Tikhonoff; Anna Bascelli; Bortolo Martini; Alberto Mazza; Sandro Caffi; Daniele D'Este; Francesco Bagato; Monica Bolzon; Federica Guidotti; Hilda Haxhi Nasto; Mario Saugo; Francesco Guglielmi; Achille C Pessina
Journal:  Eur J Epidemiol       Date:  2008-03-06       Impact factor: 8.082

6.  Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes.

Authors:  Bradley A Maron; Rui-Sheng Wang; Sergei Shevtsov; Stavros G Drakos; Elena Arons; Omar Wever-Pinzon; Gordon S Huggins; Andriy O Samokhin; William M Oldham; Yasmine Aguib; Magdi H Yacoub; Ethan J Rowin; Barry J Maron; Martin S Maron; Joseph Loscalzo
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

7.  The Groningen electrocardiographic criteria for left ventricular hypertrophy: a sex-specific analysis.

Authors:  M Yldau van der Ende; Tom Hendriks; Yordi van de Vegte; Erik Lipsic; Harold Snieder; Pim van der Harst
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.996

8.  Impact of Distal Protection with Filter-Type Device on Long-term Outcome after Percutaneous Coronary Intervention for Acute Myocardial Infarction: Clinical Results with Filtrap®.

Authors:  Ryota Teramoto; Kenji Sakata; Kenji Miwa; Takao Matsubara; Toshihiko Yasuda; Masaru Inoue; Hirofumi Okada; Honin Kanaya; Masa-Aki Kawashiri; Masakazu Yamagishi; Kenshi Hayashi
Journal:  J Atheroscler Thromb       Date:  2016-06-02       Impact factor: 4.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.